Use of high doses of botulinum toxin type A in children: Role and safety in clinical practice;Utilisation de fortes doses de toxine botulique de type A chez l'enfant: intérêt et sécurité en pratique clinique

Annales de Readaptation et de Medecine Physique

Volumn 50, Issue SUPPL. 1, 2007, Pages

  Filipetti, P ^a   Chantraine, F ^a  

^a Centre National de Rééducation Fonctionnelle et de Réadaptation   (France)

Author keywords

Botulinum Toxin; Cerebral palsy; High doses; Spasticity

Indexed keywords

BACLOFEN; BOTULINUM TOXIN A;

ARTICLE; BRAIN MATURATION; CEREBRAL PALSY; DISEASE CLASSIFICATION; DRUG EFFICACY; DRUG INDICATION; DRUG SAFETY; GAIT; HUMAN; INJECTION SITE; NERVOUS SYSTEM DEVELOPMENT; PATHOPHYSIOLOGY; PATIENT CARE; SPASTICITY;

BOTULINUM TOXIN TYPE A; CEREBRAL PALSY; CHILD; DOSE-RESPONSE RELATIONSHIP, DRUG; HUMANS; NEUROMUSCULAR AGENTS; SAFETY;

EID: 34250025924     PISSN: 01686054     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0168-6054(07)80003-1     Document Type: Article

References (17)

1. Amiel-Tison C. Neurologie périnatale (2002), Masson
2. Awaad Y., Tayem H., Soliman S., Munoz S., Thomas Soliman S., Michon A.M., et al. High dose of botulinum toxin type-A (BTX/A) : safety and efficacy in patients with cerebral palsy. J Pediatr Neurol 2 2 (2004) 91-96
3. Gage J.R. The treatment of gait problems in cerebral palsy (2004), Mac Keith Press, Paris
4. Goldstein E.M. Safety of high-dose botulinum toxin type A therapy for the treatment of pediatric spasticity. J Child Neurol 21 3 (2006) 189-192
5. Graham H.K. Recommendations for the use of Botulinum toxin type a in the management of cerebral palsy. Gait Posture 11 1 (2000) 67-79
6. 14th-16th May ; Madrid. Heinen F. Management of cerebral palsy : multi-muscle options. Future experts symposium. Madrid (2006)
7. Heinen F. Interventional neuropediatrics : treatment of dystonic and spastic muscular hyperactivity with botulinum toxin A. Neuropediatrics 29 6 (1997) 307-313
8. Kinnett D. Botulinum toxin A injections in children: Technique and dosing issues. Am J Phys Med Rehabil 83 10 (2004) 9-S64
9. Koman L.A. Spasticity associated with cerebral palsy in children guidelines for the use of Botulinum A toxin. Paediatr Drugs 5 1 (2003) 11-23
10. Molenaers G. Botulinum toxin type A treatment of cerebral palsy : an integrated approach. Eur J Neurol 6 Suppl 4 (1999) 51-57
11. Nolan K.W. Use of Botulinum toxin Type A in chidren with cerebral palsy. Phys Ther 86 (2006) 573-584
12. Polak F., Morton R., Ward C., Wallace W.A., Doderlein L., and Siebel A. Double-blind comparison study of two doses of botulinum toxin A injected into calf muscles in children with hemiplegic cerebral palsy. Dev Med Child Neurol 44 8 (2002) 551-555
13. Rafalowska J. Some problems of development and ageing of the nervous system. Myelination of spinal roots in the second half of life and in early infancy. Neuropath polska 3 (1979) 407-420
14. Rodda J., and Graham H.K. Classification of gait patterns in spastic hemiplegia and spastic diplegia : a basis for management algorithm. Eur J Neurol 8 Suppl 5 (2001) 98-108
15. Satila H., Kotamaki A., Koivikko M., and Autti-Ramo I. Low and high dose botulinum toxin A treatment : a retrospective analysis. Pediatr Neurol 34 4 (2006) 285-290
16. Sutherland D.H. The development of mature walking (1988), Mac Keith Press
17. Wissel J., Heinen F., Schenkel A., Doll B., Ebersbach G., and Muller J. Botulinum toxin A in the management of spastic gait disorders in children and young adults with cerebral palsy : a randomized, dou ble-blind study of "high-dose" versus "low-dose" treatment. Neuropediatrics 30 3 (1999) 120-124